Background: Since the declaration of COVID-19 as a pandemic, measures such as nationwide lockdowns have been implemented. The sudden disruption of activities coupled with fear could trigger or aggravate mental illnesses and consequently, increase substance use as a coping mechanism. This study then sought to assess the impact of the lockdown on depression and substance use amongst students in a tertiary institution in Ibadan city, Nigeria.
Methods: A self-administered 26 questions online questionnaire was employed for data collection of socio-demographic characteristics, Patient Health Questionnaire (PHQ-9) to assess depression, and a section on the use of psychoactive drugs during lockdown. Data were statistically analyzed using IBM's SPSS and Microsoft Excel.
Results: We gathered 102 responses, 54.9% were males. Most of the respondents had mild depression (41.2%), followed by 36.3% that reported not having an episode of depression, 15.7% moderate, 4.9% moderately severe, and 2% severe depression. Female had more depressive episodes than males (p=0.185). Only 4% reported substance use since the pandemic, all were male. At a 95% confidence interval, there was no significant association between the level of depression and any socio-demographic characteristics of students and between the level of depression and drug use.
Conclusions: According to this study, lockdown and other mitigation strategies implemented during the pandemic were not found to be associated with drug use. A limitation of this study is the cross-sectional design, as a result, a larger multicenter study is needed to ascertain the possible association between lockdown, depressive symptoms, and drug use among students.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.